← Leaderboards
Scott B Snapper
Boston Children'S Hospital
$17,656,816
Attributed
$27,941,697
Total exposure
14
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.9M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$27,941,697 · 14
By mechanism
R01$12,070,846 · 4
RC2$9,093,614 · 1
T32$3,415,797 · 1
P01$1,230,203 · 1
R56$744,102 · 2
P30$740,507 · 3
Top collaborators
- Jessica R. Allegretti7 shared
- Ivan Zanoni7 shared
- Christoph Klein5 shared
- Aleixo M Muise5 shared
- David A Williams1 shared
Most similar at Boston Children'S Hospital
Same institution · by research overlap
- Christoph Klein$3,031,205
Others in their field
Top investigators on “Inflammatory Bowel Diseases”
- Judy H Cho · University Of Chicago$48,459,647
- Ramnik J Xavier · Broad Institute, Inc.$43,517,622
- Mark J Daly · Broad Institute, Inc.$37,682,914
- Richard S Blumberg · Children'S Hospital Boston$36,446,455
- Stacey Gabriel · Massachusetts Institute Of Technology$34,637,180
- Eugene B Chang · University Of Chicago$28,912,342
Research focus
Inflammatory Bowel DiseasesCellsDesignSignal TransductionTissuesMucous MembraneIntestinesMutationBaseImmuneColitisMouse ModelMediatingChronicBloodCell TypeLinkCollaborationsGeneticProteinsCollectionBiopsyGrantIn Vivo
Grant awards (56)
Training in Pediatric Gastroenterology, Hepatology, and Nutrition$782,824
T32 · FY2025 · DK · contact PI
Type III interferon Control of Mucosal Immunity$777,421
R01 · FY2025 · DK
Clinical Component$90,466
P30 · FY2025 · DK · contact PI
Identifying Immune and Epithelial Network Signatures in Very Early Onset Inflammatory Bowel Disease$1,743,199
RC2 · FY2024 · DK · contact PI
Type III interferon Control of Mucosal Immunity$746,324
R01 · FY2024 · DK
Training in Pediatric Gastroenterology, Hepatology, and Nutrition$706,588
T32 · FY2024 · DK · contact PI
Low Dose Interleukin-2 for Regulatory T cell Modulation and the Treatment of CrohnâÂÂs Disease$583,336
R01 · FY2024 · DK · contact PI
Clinical Component$90,466
P30 · FY2024 · DK · contact PI
Identifying Immune and Epithelial Network Signatures in Very Early Onset Inflammatory Bowel Disease$1,815,831
RC2 · FY2023 · DK · contact PI
Type III interferon Control of Mucosal Immunity$777,421
R01 · FY2023 · DK
Training in Pediatric Gastroenterology and Nutrition$707,066
T32 · FY2023 · DK · contact PI
Low Dose Interleukin-2 for Regulatory T cell Modulation and the Treatment of CrohnâÂÂs Disease$543,883
R01 · FY2023 · DK · contact PI
Clinical Component$90,466
P30 · FY2023 · DK · contact PI
Identifying Immune and Epithelial Network Signatures in Very Early Onset Inflammatory Bowel Disease$1,815,831
RC2 · FY2022 · DK · contact PI
Training in Pediatric Gastroenterology and Nutrition$635,520
T32 · FY2022 · DK · contact PI
Low Dose Interleukin-2 for Regulatory T cell Modulation and the Treatment of Crohn's Disease$551,543
R01 · FY2022 · DK · contact PI
Clinical Component$90,466
P30 · FY2022 · DK · contact PI
Identifying Immune and Epithelial Network Signatures in Very Early Onset Inflammatory Bowel Disease$1,812,291
RC2 · FY2021 · DK · contact PI
Training in Pediatric Gastroenterology and Nutrition$583,799
T32 · FY2021 · DK · contact PI
Low Dose Interleukin-2 for Regulatory T cell Modulation and the Treatment of CrohnâÂÂs Disease$553,742
R01 · FY2021 · DK · contact PI
Clinical Component$90,466
P30 · FY2021 · DK · contact PI
Identifying Immune and Epithelial Network Signatures in Very Early Onset Inflammatory Bowel Disease$1,906,462
RC2 · FY2020 · DK · contact PI
Type III interferon Control of Mucosal Immunity$622,835
R01 · FY2020 · DK · contact PI
Low Dose Interleukin-2 for Regulatory T cell Modulation and the Treatment of CrohnâÂÂs Disease$603,706
R01 · FY2020 · DK · contact PI
Clinical Component$60,938
P30 · FY2020 · DK · contact PI
Type III interferon Control of Mucosal Immunity$622,835
R01 · FY2019 · DK · contact PI
Low dose interleukin 2 for the expansion of regulatory T cells and the treatment of moderate to severe ulcerative colitis$172,413
R21 · FY2019 · DK · contact PI
Clinical Component$43,304
P30 · FY2019 · DK · contact PI
Type III interferon Control of Mucosal Immunity$622,835
R01 · FY2018 · DK · contact PI
Low dose interleukin 2 for the expansion of regulatory T cells and the treatment of moderate to severe ulcerative colitis$235,913
R21 · FY2018 · DK · contact PI
Clinical Component$68,080
P30 · FY2018 · DK · contact PI
Type III interferon Control of Mucosal Immunity$622,835
R01 · FY2017 · DK · contact PI
Employing novel humanized murine strains to develop hematopoietic stem cell gene therapeutic approaches for very early-onset inflammatory bowel disease due to IL10-receptor deficiency.$407,902
R56 · FY2017 · AI · contact PI
Clinical Component$65,318
P30 · FY2017 · DK · contact PI
Clinical Component$50,537
P30 · FY2016 · DK · contact PI
Exploring Regulatory T Cell Dysfunction in a Murine Model of Colitis$323,847
R01 · FY2013 · AI · contact PI
Deciphering the Role of WASP Family Proteins in T Cell Function$390,000
P01 · FY2012 · HL · contact PI
Exploring Regulatory T Cell Dysfunction in a Murine Model of Colitis$344,520
R01 · FY2012 · AI · contact PI
Deciphering the Role of WASP Family Proteins in T Cell Function$420,438
P01 · FY2011 · HL · contact PI
Exploring Regulatory T Cell Dysfunction in a Murine Model of Colitis$342,210
R01 · FY2011 · AI · contact PI
Deciphering the Role of WASP Family Proteins in T Cell Function$419,765
P01 · FY2010 · HL · contact PI
Exploring Regulatory T Cell Dysfunction in a Murine Model of Colitis$350,460
R01 · FY2010 · AI · contact PI
Exploring Regulatory T Cell Dysfunction in a Murine Model of Colitis$220,417
R01 · FY2009 · AI · contact PI
Exploring Regulatory T Cell Dysfunction in a Murine Model of Colitis$90,087
R01 · FY2009 · AI · contact PI
Exploring Regulatory T Cell Dysfunction in a Murine Model of Colitis$9,095
R01 · FY2009 · AI · contact PI
Exploring Regulatory T Cell Dysfunction in a Murine Model of Colitis$336,200
R56 · FY2008 · AI · contact PI
Cytoskeletal-Pathogen Interactions in Shigella Infection$403,167
R01 · FY2007 · AI · contact PI
Cytoskeletal-Pathogen Interactions in Shigella Infection$415,208
R01 · FY2006 · AI · contact PI
Cytoskeletal-Pathogen Interactions in Shigella Infection$421,550
R01 · FY2005 · AI
Cytoskeletal-Pathogen Interactions in Shigella Infection$417,900
R01 · FY2004 · AI
The Pathogenesis Of Colitis In A Novel Th2 Model Of IBD$317,177
R01 · FY2004 · AI
The Pathogenesis Of Colitis In A Novel Th2 Model Of IBD$317,177
R01 · FY2003 · AI
Cytoskeletal-Pathogen Interactions in Shigella Infection$148,083
R01 · FY2003 · AI
The Pathogenesis Of Colitis In A Novel Th2 Model Of IBD$321,232
R01 · FY2002 · AI
MOLECULAR AND GENETIC ANALYSIS OF A BLOOD CELL DISEASE$119,151
K08 · FY2001 · HL
MOLECULAR AND GENETIC ANALYSIS OF A BLOOD CELL DISEASE$119,151
K08 · FY2000 · HL